| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015461 |
| Receipt No. | R000017957 |
| Official scientific title of the study | Feasibility study on detecting EGFR T790M mutation in cell free DNA from advanced non small cell lung cancer patients refractory to EGFR-TKI:WJOG8014LTR |
| Date of disclosure of the study information | 2014/10/17 |
| Last modified on | 2018/03/13 (Ver. 8) |
| Basic information | ||
| Official scientific title of the study | Feasibility study on detecting EGFR T790M mutation in cell free DNA
from advanced non small cell lung cancer patients refractory to EGFR-TKI:WJOG8014LTR |
|
| Title of the study (Brief title) | Feasibility study on detecting EGFR T790M mutation in cell free DNA
from advanced non small cell lung cancer patients refractory to EGFR-TKI |
|
| Region |
|
|
| Condition | |||
| Condition | Advanced non-small cell lung cancer with EGFR mutation | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | YES | ||
| Objectives | |
| Narrative objectives1 | To evaluate the procedure for detecting EGFR T790M mutation in cell free DNA from advanced non small cell lung cancer patients refractory to EGFR-TKI |
| Basic objectives2 | Others |
| Basic objectives -Others | o evaluate the feasibility of detecting EGFR T790M mutation in cell free DNA from advanced non-small cell lung cancer patients |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | feasibility of detecting EGFR T790M mutation in cell free DNA
from advanced non small cell lung cancer patients refractory to EGFR-TKI |
| Key secondary outcomes | detection rate of EGFR T790M mutations in plasma
concordance of EGFR mutation status between tissue sample and plasma correlation between EGFR mutation status and clinical background |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) advanced non-small cell lung cancer harboring EGFR mutations
2) refractory to EGFR-TKI monotherapy or combination therapy * accept patients receiving EGFR-TKI therapy beyond PD with or without local therapy such as radiation therapy for brain or bone metastasis 3) written informed consent obtained from the patient |
|||
| Key exclusion criteria | Not applicable | |||
| Target sample size | 155 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuto Nishio |
| Organization | Kinki University |
| Division name | Faculty of Medicine, Dept. of Genome Biology |
| Address | 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511 |
| TEL | 072-366-0221 |
| knishio@med.kindai.ac.jp | |
| Public contact | |
| Name of contact person | Shinichiro Nakamura |
| Organization | West Japan Oncology Group |
| Division name | datacenter |
| Address | Namba Plaza Bldg.3F 1-5-7,Motomachi Naniwa-ku,Osaka 556-0016 JAPAN |
| TEL | 06-6633-7400 |
| Homepage URL | |
| datacenter@wjog.jp | |
| Sponsor | |
| Institute | West Japan Oncology Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Astellas Pharma Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Kinki University Faculty of Medicine, Dept. of Genome Biology |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | https://www.ncbi.nlm.nih.gov/pubmed/27542267 |
| Results | |
| Other related information | Nothing particular |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017957 |